This episode focuses on missed opportunities to intensify lipid-lowering therapy, highlighting gaps where treatment escalation could improve lipid management and cardiovascular risk reduction. The discussion centers on recognizing when lipid control is inadequate and on the role of the clinical pharmacist in optimizing medications, including PCSK9i, statins, and emerging therapies, to better align with patient risk and treatment goals. Read the full article at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70209

Drs. Shannon Finks and Sarah McBane discuss their July 2026 narrative review, “Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.” They describe menopause as a multisystem transition with vasomotor, mood/cognitive, cardiometabolic, and genitourinary symptoms, noting many women see multiple clinicians before diagnosis. They emphasize that menopausal hormone therapy (MHT) formulation, route, timing, and patient selection matter. They discuss MHT benefits for symptom relief, bone protection, and genitourinary symptoms, nuances around cardiovascular, cancer, and cognition outcomes, FDA labeling updates, and more. The manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70178

Artificial intelligence (AI) is reshaping how research gets done — and pharmacy practice is no exception. In this episode, Editor-in-Chief Stuart T. Haines sits down with Katie Trinkley, Associate Professor of Medicine at the University of Colorado School of Medicine. Dr. Trinkley recently authored an invited paper in JACCP on Research and Scholarly Methods series regarding the use of AI, and she joins us to unpack what pharmacy researchers need to know right now. From the fundamental differences between predictive and generative AI, to the build-versus-buy decision, to AI's underappreciated role in qualitative research, this conversation offers a practical, rigorous framework for using AI thoughtfully — and why pharmacists are uniquely positioned to lead the way. Read the full manuscript: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70239

The first in a series of interviews with different leaders in clinical pharmacy: Dr. Peter H. Vlasses. 

Drs. Alan Zillich and Khoa Nguyen speak with Drs. Kathryn Lin and Morgan Stewart (University of Texas at Austin) and Dr. Tony Olson (Geisinger) about clinical pharmacists using ambientAI documentation tools in ambulatory care.

The guests describe workflows using mobile apps integrated with Epic, consent processes, and pharmacist review/editing before signing notes. They discuss implementation rollouts,benefits such as reduced documentation burden, improved attention during encounters, less after-hours work, and support for bilingual Spanish-English visits, as well as challenges like inaccuracies, paraphrasing, and considerations for training student learners. Listen as they summarize their study findings and read the full manuscript here: ⁠https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70242.

Host Dr. Michael Rybak interviews Drs. Alejandro Perez and Autumn Brenner (UNC Medical Center) about their retrospective study, “Incidence of Acute Kidney Injury with the Use of Nafcillin versus Oxacillin,” comparing 171 nafcillin patients with 467 oxacillin patients. The study found a higher AKI rate with nafcillin (33.3%) versus oxacillin (19.5%), along with higher hypokalemia, suggesting these agents may not be clinically interchangeable from a safety standpoint. They discuss confounding concerns around observed mortality and length-of-stay differences, offer mechanistic explanations, and recommend close monitoring of creatinine and potassium—especially in high-risk patients.

Host Dr. Tom Lodise interviews Dr. Marc Scheetz about his Pharmacotherapy editorial, “AI in ID Pharmacy: We Should Not Be Afraid to Put the CAR (Not the Cart) Before the Horse,” discussing how AI is already mainstream and increasingly used in healthcare. Scheetz uses the Industrial Revolution and the John Henry story to argue clinicians should not compete with machines but learn to make them work with us, as AI can outperform humans in many tasks. His optimistic view is that AI will reduce computer-bound work and preserve human connection in patient care. Read the full editorial at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70103

In this episode of the JACCP Podcast, host Rob DiDomenico is joined by JACCP Editor in Chief Stuart Haines and Senior Associate Editor Beth Phillips to offer practical guidance for authors seeking to publish in the Journal of the American College of Clinical Pharmacy. With nearly 500 annual submissions and a rejection rate approaching 90% for unsolicited manuscripts, it’s important to put together a strong submission. The conversation covers the journal's scope and mission and addresses the most common reasons manuscripts are rejected, from methodological weaknesses to unsupported conclusions. Stuart and Beth also share actionable tips on following reporting guidelines, strengthening review articles, and exploring the journal's full range of manuscript types. A recurring theme: don't hesitate to pitch your idea before investing weeks in writing.

Dr. Ryan Carnahan, Pharmacotherapy's statistical scientific editor, interviews Dr. Jenny Lo-Ciganic about her research on the use of machine learning models to predict fall-related injuries among older adults with depression. Lo-Ciganic describes her work using real-world data and advanced analytics to improve medication safety and decision support. The discussion reviews the burden of falls and how depression increases risk, noting prior antidepressant–fall associations may reflect confounding by indication. They also address key injurious fall predictors, including frailty, age, prior falls, osteoarthritis, antidepressant dose, and regional social/health measures. Read the full manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/ftr/10.1002/phar.70087.

JACCP associate editor and host, Erica Ernst, interviews Drs. Wendy St. Peter and Barbara Zarowitz discuss adopting race-free estimated GFR (CKD-EPI) for medication-related kidney function assessment in older adults and other patient populations, as well as moving away from the Cockcroft–Gault equation. The discussion highlights deficiencies and variabilityin Cockcroft–Gault use, emerging studies where BSA-adjusted eGFR better predicts drug clearance, barriers to cystatin C access and Medicare coverage, and the need for further research, electronic health record integration, and advocacy across organizations. Read the original article and series of letters published in JACCP.